Welcome to our dedicated page for Global Medical news (Ticker: GMRE), a resource for investors and traders seeking the latest updates and insights on Global Medical stock.
Global Medical REIT Inc. (NYSE: GMRE) is a net-lease medical real estate investment trust that acquires healthcare facilities and leases them to physician groups and regional and national healthcare systems. This news page aggregates company announcements, earnings releases and transaction updates so readers can follow how GMRE manages its healthcare real estate portfolio, capital structure and dividend policy over time.
News items for GMRE often cover quarterly and year-to-date financial results, including rental revenue trends, net income or loss, Funds From Operations (FFO), Adjusted Funds From Operations (AFFO), Funds Available for Distribution (FAD) and same-store cash net operating income. The company also reports portfolio metrics such as occupancy, leasable square footage, annualized base rent, weighted average lease term and the mix of outpatient medical buildings, inpatient rehabilitation facilities, hospitals and other medical real estate.
Investors can use this feed to track Global Medical REIT’s investment activity, such as acquisitions of medical real estate portfolios, property dispositions, and significant leasing events at key facilities. Capital markets and balance sheet developments are another recurring theme, including amendments to the company’s credit facility, interest rate hedging through forward-starting swaps, and offerings of preferred stock like the 8.00% Series B Cumulative Redeemable Preferred Stock.
Governance and corporate actions are also reflected in GMRE’s news, including changes in executive leadership, employment agreements with senior management, board retirements, the authorization of a common stock repurchase program and corporate actions such as the one-for-five reverse stock split of its common stock. For income-focused readers, dividend declarations on common and preferred shares are regularly announced with record and payment details. Bookmark this page to review Global Medical REIT’s latest disclosures and historical announcements in one place.
Global Medical REIT (NYSE: GMRE) will release fourth quarter and year-end 2025 results after market close on Wednesday, February 25, 2026, followed by a webcast and conference call on Thursday, February 26, 2026 at 9:00 a.m. ET. At the time of the release, the company’s name change to Chiron Real Estate will be effective.
Management participants include CEO Mark Decker, Jr., CFO Robert Kiernan, CIO Alfonzo Leon and COO Danica Holley. A replay will be available Feb 26–Mar 12, 2026, and the webcast archive will be posted on the investor website.
Global Medical REIT (NYSE: GMRE) will rebrand as Chiron Real Estate Inc. effective 12:01 a.m. ET on February 23, 2026, and will trade under ticker XRN. The change also updates its preferred tickers to XRN PrA and XRN PrB.
The rebrand does not alter organizational structure, stockholder rights, REIT tax qualification, outstanding securities validity, or CUSIP numbers. A new corporate website www.chironre.com and an investor presentation aligned with 2026 strategic objectives will be published on February 23, 2026.
Global Medical REIT (NYSE: GMRE) posted information on the federal income tax treatment of dividends paid in 2025 on its common stock and Series A preferred stock. Tax details and adjusted dividend amounts reflecting the one-for-five reverse stock split effective September 19, 2025, are available on the company's investor website.
Stockholders are advised to compare the posted data with their Forms 1099 and other 2025 brokerage tax statements and to consult professional tax advisors for individual tax consequences.
Global Medical REIT (NYSE: GMRE) announced that Henry Cole will step down from the Board of Directors at the end of his current term, effective at the Company’s 2026 Annual Meeting of Stockholders. Mr. Cole served as an independent director since inception and previously held roles including Lead Independent Director, Chair of the Compensation and ESG Committees, and member of the Audit and Nominating and Corporate Governance Committees. The Board thanked Mr. Cole for his leadership and contributions and wished him well in his future pursuits.
Global Medical REIT (NYSE: GMRE) announced the planned retirement of director Ronald Marston, effective at the end of his current term at the Company’s 2026 Annual Meeting of Stockholders.
The Board declared the 2025 fourth quarter dividends: a $0.75 per share common cash dividend payable on January 9, 2026 to holders of record as of December 19, 2025; a $0.46875 per share quarterly cash dividend on Series A preferred payable on February 2, 2026 to holders of record as of January 15, 2026; and an initial pro rata $0.388 per share quarterly cash dividend on Series B preferred payable on February 2, 2026 to holders of record as of January 15, 2026.
Global Medical REIT (NYSE:GMRE) priced an underwritten public offering of 2,000,000 shares of its 8.00% Series B Cumulative Redeemable Preferred Stock with an initial liquidation preference of $25.00 per share. The offering is expected to close on November 20, 2025, subject to customary conditions, with gross proceeds of approximately $50,000,000. The company granted underwriters a 30-day option to purchase up to 300,000 additional shares to cover over-allotments. Net proceeds may be used for general corporate purposes, including funding acquisitions and repaying amounts outstanding under the company credit facility. The company intends to apply to list the shares on the NYSE under GMRE PrB.
Global Medical REIT (NYSE:GMRE) announced an underwritten public offering of its Series B Cumulative Redeemable Preferred Stock, $0.001 par value per share, subject to market conditions.
The company expects to grant underwriters a 30-day option for over-allotments, intends to use net proceeds for general corporate purposes including possible acquisitions and debt repayment, and plans to list the shares on the New York Stock Exchange under GMRE-PrB. Raymond James, BMO Capital Markets, Stifel and Baird are book-running managers. The offering is made under a shelf registration declared effective by the SEC on April 4, 2024.
Global Medical REIT (NYSE: GMRE) reported Q3 2025 results and corporate actions on November 4, 2025. Q3 net loss was $6.0M, or $0.45 per diluted share, driven primarily by a $6.3M impairment on an Aurora, IL facility that was sold. FFO rose to $14.5M ($1.00/share), and AFFO rose to $16.2M ($1.12/share), each up ~4% year-over-year on a per-share basis. Same-store cash NOI grew 2.7%. Portfolio occupancy was 95.2%; consolidated debt was $710M (leverage 47.3%) with a 4.06% weighted average interest rate. The company completed a one-for-five reverse split, established a $50M buyback program, and amended its credit facility to extend maturities and hedge term loan SOFR exposure.
Global Medical REIT (NYSE: GMRE) will release its third quarter 2025 financial results after market close on Tuesday, November 4, 2025.
The company will host a conference call and live webcast on Wednesday, November 5, 2025 at 9:00 a.m. Eastern Time, with President & CEO Mark Decker Jr., CFO Robert Kiernan, CIO Alfonzo Leon, and COO Danica Holley participating.
Investors may join via live webcast at https://investors.globalmedicalreit.com/news-events/ir-calendar (preferred). U.S. dial-in: 1-877-300-8521; international dial-in: 1-412-317-6026. A replay will be available from ~12:00 p.m. ET on Nov 5, 2025 through 11:59 p.m. ET on Nov 19, 2025 (replay dial-in: domestic 1-844-512-2921, international 1-412-317-6671, passcode 10203242).
Global Medical REIT (NYSE: GMRE) entered an amended and restated credit facility on October 8, 2025 that extends maturities and hedges interest-rate exposure.
Key changes: $400M revolver maturity extended to Oct 2029 with election to extend to Oct 2030; the existing $350M Term Loan A is split into A-1 $100M (Oct 2029), A-2 $100M (Oct 2030), and A-3 $150M (Apr 2031); the prior 0.10% SOFR spread adjustment was removed; and a $350M package of forward-starting interest-rate swaps was entered to hedge SOFR on the three Term Loan A tranches. Reported fixed swap bases are 3.24%–3.32% yielding effective rates of 4.75%–4.84% (inclusive of spreads). At close the weighted average debt term increased from 1.3 years to 4.4 years.